

Chengjie Xiong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7202284/publications.pdf>

Version: 2024-02-01

115
papers

4,941
citations

117625

34
h-index

106344

65
g-index

137
all docs

137
docs citations

137
times ranked

5952
citing authors

#	ARTICLE	IF	CITATIONS
1	High-precision plasma β -amyloid 42/40 predicts current and future brain amyloidosis. <i>Neurology</i> , 2019, 93, e1647-e1659.	1.1	514
2	Symptom onset in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2014, 83, 253-260.	1.1	391
3	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 398-407.	30.7	351
4	Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. <i>JAMA Neurology</i> , 2015, 72, 1029.	9.0	237
5	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 264.	9.0	227
6	Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	208
7	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. <i>Neurology</i> , 2018, 91, e1295-e1306.	1.1	193
8	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. <i>Alzheimer's and Dementia</i> , 2018, 14, 1460-1469.	0.8	192
9	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	30.7	182
10	Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 869-879.	0.8	113
11	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 59.	6.2	101
12	Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). <i>Lancet Neurology</i> , The, 2016, 15, 1317-1325.	10.2	87
13	Measuring and estimating diagnostic accuracy when there are three ordinal diagnostic groups. <i>Statistics in Medicine</i> , 2006, 25, 1251-1273.	1.6	84
14	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	2.4	84
15	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. <i>Annals of Neurology</i> , 2016, 80, 379-387.	5.3	82
16	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018, 141, 1486-1500.	7.6	79
17	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. <i>NeuroImage: Clinical</i> , 2018, 19, 406-416.	2.7	76
18	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 655-665.	0.8	72

#	ARTICLE	IF	CITATIONS
19	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. <i>Lancet Neurology</i> , The, 2022, 21, 329-341.	10.2	72
20	Effect of Race on Prediction of Brain Amyloidosis by Plasma A β ²⁴² /A β ²⁴⁰ , Phosphorylated Tau, and Neurofilament Light. <i>Neurology</i> , 2022, 99, .	1.1	63
21	Factors Associated With the Onset and Persistence of Post-Lumbar Puncture Headache. <i>JAMA Neurology</i> , 2015, 72, 325.	9.0	59
22	Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. <i>Neurobiology of Aging</i> , 2017, 56, 25-32.	3.1	57
23	Youden Index and Associated Cut-Points for Three Ordinal Diagnostic Groups. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2013, 42, 1213-1234.	1.2	56
24	Role of Family History for Alzheimer Biomarker Abnormalities in the Adult Children Study. <i>Archives of Neurology</i> , 2011, 68, 1313.	4.5	55
25	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1427-1437.	0.8	51
26	Upward drift in cerebrospinal fluid amyloid β ²⁴² assay values for more than 10 years. <i>Alzheimer's and Dementia</i> , 2018, 14, 62-70.	0.8	50
27	Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. <i>Neurobiology of Aging</i> , 2016, 43, 23-33.	3.1	49
28	A Clinical Study of Lupron Depot in the Treatment of Women with Alzheimer's Disease: Preservation of Cognitive Function in Patients Taking an Acetylcholinesterase Inhibitor and Treated with High Dose Lupron Over 48 Weeks. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 549-560.	2.6	47
29	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016, 11, e0152082.	2.5	45
30	Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 745-756.	2.6	45
31	Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 1149-1159.	0.8	45
32	Preclinical Alzheimer's disease and longitudinal driving decline. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 74-82.	3.7	44
33	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 1225.	3.3	42
34	Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. <i>Neurology</i> , 2016, 86, 1499-1506.	1.1	39
35	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2019, 142, 1429-1440.	7.6	36
36	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. <i>Neurobiology of Aging</i> , 2019, 75, 42-50.	3.1	36

#	ARTICLE	IF	CITATIONS
37	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. <i>Neurology</i> , 2021, 97, e1823-e1834.	1.1	35
38	A novel cognitive disease progression model for clinical trials in autosomal dominant Alzheimer's disease. <i>Statistics in Medicine</i> , 2018, 37, 3047-3055.	1.6	31
39	Risk of incident clinical diagnosis of Alzheimer's disease type dementia attributable to pathology confirmed vascular disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 613-623.	0.8	30
40	Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset. <i>Alzheimer's and Dementia</i> , 2019, 15, 506-514.	0.8	28
41	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2015, 85, 790-798.	1.1	27
42	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. <i>Neurology: Genetics</i> , 2021, 7, e571.	1.9	27
43	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2021, 20, 615-626.	10.2	26
44	Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 589-597.	0.8	25
45	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. <i>Brain</i> , 2018, 141, 3233-3248.	7.6	24
46	A Parametric Comparison of Diagnostic Accuracy with Three Ordinal Diagnostic Groups. <i>Biometrical Journal</i> , 2007, 49, 682-693.	1.0	22
47	Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	7.6	20
48	Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 84, 741-753.	5.3	17
49	Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. <i>Information Fusion</i> , 2020, 58, 153-167.	19.1	17
50	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102491.	2.7	17
51	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.1	16
52	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 669-677.	2.4	14
53	Item response theory analysis of the Clinical Dementia Rating. <i>Alzheimer's and Dementia</i> , 2021, 17, 534-542.	0.8	14
54	Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain. <i>Neurobiology of Aging</i> , 2020, 96, 165-175.	3.1	13

#	ARTICLE	IF	CITATIONS
55	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). <i>Alzheimer's and Dementia</i> , 2020, 16, 219-228.	0.8	13
56	Bivariate correlation coefficients in family-type clustered studies. <i>Biometrical Journal</i> , 2015, 57, 1084-1109.	1.0	12
57	Lack of association between acute stroke, post-stroke dementia, race, and β -amyloid status. <i>NeuroImage: Clinical</i> , 2021, 29, 102553.	2.7	12
58	Interrater Reliability of the Record of Driving Errors (RODE). <i>American Journal of Occupational Therapy</i> , 2015, 69, 6902350020p1-6902350020p6.	0.3	10
59	Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 669-676.	3.7	9
60	Falls: a marker of preclinical Alzheimer disease: a cohort study protocol. <i>BMJ Open</i> , 2021, 11, e050820.	1.9	8
61	Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults. <i>Alzheimer's and Dementia</i> , 2022, 18, 2570-2581.	0.8	8
62	A multiple imputation approach to the analysis of clustered interval-censored failure time data with the additive hazards model. <i>Computational Statistics and Data Analysis</i> , 2016, 103, 242-249.	1.2	7
63	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. <i>Alzheimer's and Dementia</i> , 2019, 15, 1448-1457.	0.8	7
64	Estimating correlation between multivariate longitudinal data in the presence of heterogeneity. <i>BMC Medical Research Methodology</i> , 2017, 17, 124.	3.1	6
65	Identifying blood pressure loci whose effects are modulated by multiple lifestyle exposures. <i>Genetic Epidemiology</i> , 2020, 44, 629-641.	1.3	6
66	Optimizing parameters in clinical trials with a randomized start or withdrawal design. <i>Computational Statistics and Data Analysis</i> , 2014, 69, 101-113.	1.2	4
67	Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1754-1764.	0.8	4
68	Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 153.	6.2	3
69	P1 ⁰²³ : MASS SPECTROMETRY-BASED MEASUREMENT OF LONGITUDINAL CSF TAU IDENTIFIES DIFFERENT PHOSPHORYLATED SITES THAT TRACK DISTINCT STAGES OF PRESYMPTOMATIC DOMINANTLY INHERITED AD. <i>Alzheimer's and Dementia</i> , 2018, 14, P273.	0.8	2
70	MINIMIZING THE SAMPLE SIZES OF CLINICAL TRIALS ON PRECLINICAL AND EARLY SYMPTOMATIC STAGE OF ALZHEIMER DISEASE. <i>Journal of prevention of Alzheimer's disease</i> , The, 2018, 5, 1-10.	2.7	2
71	Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 450-457.	3.7	2
72	Statistical estimation and comparison of group-specific bivariate correlation coefficients in family-type clustered studies. <i>Journal of Applied Statistics</i> , 0, , 1-25.	1.3	2

#	ARTICLE	IF	CITATIONS
73	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , .	0.8	2
74	O2â€06â€01: Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study. <i>Alzheimer's and Dementia</i> , 2012, 8, P244.	0.8	1
75	P2-130: Amyloid imaging and cerebrospinal fluid biomarkers predict driving performance in preclinical Alzheimer's disease. , 2015, 11, P533-P534.		1
76	Predicting Clinical Binary Outcome Using Multivariate Longitudi nal Data: Application to Patients with Newly Diagnosed Primary Open - Angle Glaucoma. <i>Journal of Biometrics & Biostatistics</i> , 2015, 06, .	4.0	1
77	A family of estimators to diagnostic accuracy when candidate tests are subject to detection limitsâ€™ Application to diagnosing early stage Alzheimer disease. <i>Statistical Methods in Medical Research</i> , 2022, 31, 882-898.	1.5	1
78	O2-01-01: Plasma and Cerebrospinal Fluid Markers in the DIAN Study of Autosomal-Dominant Alzheimer's Disease. , 2011, 7, S287-S287.		0
79	IC-O2-01: How do we define amyloid positivity in an asymptomatic population? Comparison of CSF, quantitative PET and clinical PET examinations. , 2013, 9, P6-P6.		0
80	IC-P-008: REGIONAL PIB DEPOSITION AND CSF AÎ²42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY. , 2014, 10, P11-P11.		0
81	P1-143: LONGITUDINAL CHANGES IN CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE: FINDINGS FROM A COGNITIVELY NORMAL, MIDDLE-AGED COHORT. , 2014, 10, P352-P353.		0
82	S3-01-01: SCREENING FOR ALZHEIMER'S DISEASE IN COGNITIVELY NORMAL OLDER ADULTS: SUBJECTIVE COGNITIVE DECLINE VERSUS INFORMANT REPORT. , 2014, 10, P200-P200.		0
83	O2-05-04: REGIONAL PIB DEPOSITION AND CSF AB42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY. , 2014, 10, P173-P173.		0
84	P1-149: CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE. , 2014, 10, P355-P355.		0
85	FTS-03-03: THE DIAN-TU. , 2014, 10, P247-P247.		0
86	P1-104: CSF tau predicts working memory and global cognitive decline in autosomal dominant Alzheimer's disease. , 2015, 11, P379-P379.		0
87	O3-14-03: Novel fluid biomarkers for brain amyloid and dementia risk in presymptomatic Alzheimer disease. , 2015, 11, P255-P255.		0
88	IC-P-051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P41-P41.		0
89	P2-138: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication. , 2015, 11, P538-P538.		0
90	IC-P-052: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PIB, and cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease. , 2015, 11, P41-P41.		0

#	ARTICLE	IF	CITATIONS
91	IC-03-02: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication. , 2015, 11, P8-P9.		0
92	P3-132: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PiB, and cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease. , 2015, 11, P674-P674.		0
93	P1-106: Longitudinal biomarker connectivity on middle-aged asymptomatic individuals and optimal design on prevention trials of Alzheimer's disease. , 2015, 11, P379-P379.		0
94	O2-01-03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P172-P172.		0
95	ICâ€Pâ€117: Neuronal Injury and Degeneration Evaluated With Imaging and CSF Biomarkers in Autosomal Dominant AD: Results From The Dian Study. Alzheimer's and Dementia, 2016, 12, P87.	0.8	0
96	P4â€004: Planning Dose Escalation in Phase III Clinical Trials May Prevent Underpowered Trials and Mitigate the Increase in Sample Size or Duration of Adaptive Trials. Alzheimer's and Dementia, 2016, 12, P1015.	0.8	0
97	P4â€150: Preclinical Alzheimerâ€™s Disease Predicts Longitudinal Onset of Driving Difficulties Among Cognitively Normal Persons. Alzheimer's and Dementia, 2016, 12, P1071.	0.8	0
98	O2â€08â€05: Neuronal Injury and Degeneration Evaluated with Imaging and CSF Biomarkers in Autosomal Dominant Alzheimer's Disease: Results from the Dian Study. Alzheimer's and Dementia, 2016, 12, P246.	0.8	0
99	O3-09-05: The Dian-Nacc UDS Comparison Study: Rates of Cognitive Decline. , 2016, 12, P309-P309.		0
100	F4â€03â€02: The Dominantly Inherited Alzheimer Network Trials Unit. Alzheimer's and Dementia, 2016, 12, P326.	0.8	0
101	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network. , 2016, 12, P378-P379.		0
102	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.8	0
103	[P3â€263]: MOTOR SYMPTOMS IN FAMILIAL ALZHEIMER'S DISEASE: FREQUENCY, SEVERITY AND PREDICTIVE VALUE. Alzheimer's and Dementia, 2017, 13, P1043.	0.8	0
104	[P2â€372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P768.	0.8	0
105	[ICâ€Pâ€054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P44.	0.8	0
106	[ICâ€Pâ€166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P125.	0.8	0
107	[P2â€209]: QUANTIFYING PRECLINICAL STAGES OF AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD) AND THE ASSOCIATED OVERALL BIOMARKER SIGNATURE ACROSS MODALITIES USING THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN). Alzheimer's and Dementia, 2017, 13, P689.	0.8	0
108	[O1â€02â€03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0

#	ARTICLE	IF	CITATIONS
109	[02â€“01â€“05]: IMPACT OF COGNITIVE RESERVE AND PRECLINICAL AD ON LONGITUDINAL DRIVING PERFORMANCE. Alzheimer's and Dementia, 2017, 13, P550.	0.8	0
110	[02â€“05â€“03]: CONCORDANCE BETWEEN CSF AD BIOMARKERS MEASURED BY THE AUTOMATED ELECSYS ASSAY AND <i>IN VIVO</i> AMYLOID IMAGING. Alzheimer's and Dementia, 2017, 13, P561.	0.8	0
111	[03â€“10â€“01]: CROSSâ€“SECTIONAL AND LONGITUDINAL COMPARISONS OF COGNITION AND BIOMARKERS AMONG COGNITIVELY NORMAL INDIVIDUALS AGED 42 TO 65 YEARS WITH A FAMILY HISTORY OF EITHER AUTOSOMAL DOMINANT AD (ADAD) OR LATEâ€“ONSET AD (LOAD). Alzheimer's and Dementia, 2017, 13, P923.	0.8	0
112	[01â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
113	O3â€“14â€“01: NOVEL CSF BIOMARKERS OF NEURONAL INJURY, SYNAPTIC DYSFUNCTION AND NEUROINFLAMMATION IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: VILIPâ€“1, NEUROGRANIN, SNAPâ€“25 AND YKLâ€“40 IN THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN). Alzheimer's and Dementia, 2018, 14, P1059.	0.8	0
114	ICâ€“Pâ€“046: CEREBRAL AMYLOID ANGIOPATHY IS MORE SEVERE IN AUTOSOMAL DOMINANT AD CASES WITH CEREBRAL MICROHEMORRHAGES: RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2019, 15, P48.	0.8	0
115	Incorporating Biomarkers to Improve Statistical Power of Immunotherapeutic Neoadjuvant Clinical Trials in Patients with Triple-Negative Breast Cancer. Statistics in Biopharmaceutical Research, 2019, 11, 210-219.	0.8	0